Bullfrog AI (BFRG) vs Cellectar Biosciences (CLRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bullfrog AI (BFRG) has outperformed Cellectar Biosciences (CLRB) over the past year, losing 55.6% versus a loss of 70.7%. Cellectar Biosciences is the larger company by market cap ($13.2 million vs $12.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BFRG | CLRB |
|---|---|---|
| Share price | $0.6924 | $1.40 |
| Market cap | $12.84M | $13.23M |
| 1-day change | -2.29% | -7.28% |
| YTD return | -21.59% | -52.54% |
| 1-year return | -55.62% | -70.71% |
| 5-year return | — | -99.49% |
| EPS (TTM) | $-0.46 | $-3.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.96 | $5.07 |
| 52-week low | $0.425 | $1.34 |
| Distance from 52-week high | -64.67% | -72.39% |
| Analyst consensus | none | none |
| Avg. price target upside | — | +721.43% |
| Average volume | 5.34M | 63.86K |
| Shares outstanding | 18.54M | 9.45M |
| Employees | 9 | 11 |
| Sector | Healthcare | Healthcare |
| Industry | Health Information Services | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BFRG has outperformed CLRB by 15.1 percentage points over the past year.
About Bullfrog AI
BFRG stock →Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States.
Healthcare · Health Information Services · 9 employees
About Cellectar Biosciences
CLRB stock →Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
Healthcare · Biotechnology · 11 employees
BFRG vs CLRB FAQ
Which is bigger, Bullfrog AI or Cellectar Biosciences?
Cellectar Biosciences (CLRB) is larger, with a market capitalization of $13.23M compared with $12.84M for Bullfrog AI (BFRG).
Which stock has performed better over the past year, BFRG or CLRB?
BFRG returned -55.62% over the past 12 months, compared with -70.71% for CLRB (price return, excluding dividends). Past performance does not predict future results.
Are Bullfrog AI and Cellectar Biosciences in the same industry?
Both are in the Healthcare sector, but in different industries: Health Information Services for Bullfrog AI and Biotechnology for Cellectar Biosciences.